December 6, 2016 Joshua Grill, PhD, and Aimee Pierce, MD This week, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego, we will likely learn more about the recent announcement from Eli Lilly and company that their Phase 3 clinical trial of the monoclonal antibody against the soluble form of beta amyloid, solanezumab, did not demonstrate adequate efficacy to pursue approval from the U.S. Food and Drug Administration. Until then, here is what we do know: The drug solanezumab failed, but the trial didn’t. The purpose of the trial was to measure whether solanezumab was safe and…
Read More
December 1, 2016 KCAL9/CBS2 If you missed UCI MIND Gala Co-Chairs, Lucy & Roger Lisabeth, on KCAL 9 last night, tune into CBS 2 Los Angeles tonight at 5pm with Elsa Ramon to hear their powerful story. Learn more about what the Lisabeths and UCI MIND are doing in the fight against Alzheimer's disease here.
Read More
